Global Blood Therapeutics, Inc. announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs. At GBT, Ms. Wagner will create and lead the Company’s government affairs and public policy function, initially focused on concerns related to the sickle cell disease (SCD) community. GBT is currently developing voxelotor, an oral, once-daily therapy, as a potentially disease-modifying therapy for SCD.